Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

Precision Spine, Inc., a U.S.-based leader in the design, development, and manufacturing of a comprehensive portfolio of innovative spinal pathology devices, announced today that Christopher A.

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

Trading options can be one of the most lucrative ways to make money in the stock market. But many people miss out on these profits because they believe options are too complex, risky, or that you ...